Details:
MediWound granted GENFA MEDICA SA right to distribute NexoBrid® in France and Switzerland and Specialty Therapeutics the right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: MediWound
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2020